Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Leukosite (LKST)promising new biotech Cy? -- Ignore unavailable to you. Want to Upgrade?

To: Matthew S. Aas who wrote (10)	6/9/1998 12:33:00 PM
From: ACC	Respond to of 35

Hello, everyone - just joining SI, and this thread in particular... << I think this baby will come around more sooner than later. >> Hope so too... Interesting news in the June 6 Lancet (vol 351:1701-1702): (Sorry but I couldn't get to any on-line access for this article) "Prope (Almost) tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients" from Cambridge and Therapeutic Anitbody Centre (home of H. Waldmann on LKST advisory board) To summarize: Thirteen patients undergoing kidney transplantation from 6/97-11/97 received Campath 1H as induction therapy (at time of transplantation). One documented episode of rejection, two patients with impaired kidney function, 12/13 on only single drug immunosuppression (cyclosporine). Follow-up is only 6-12 months and there is no data on infectious complications, or on the patient's immune responses after Campath 1H. Typically, this soon following transplantation, most patients are on at least three drugs for immunosuppression, with moderately higher incidence of rejection. Somewhat encouraging data for Campath 1H - does LKST have license for its use in transplantation as well as leukemia trials, through its collaboration with TAC or otherwise? The company brochure only mentions using LDP-01 (not LDP-03) for clinical trials in England... ACC